The U.S. Food and Drug Administration (FDA) has increasingly used the accelerated pathway to bring potentially lifesaving drugs to market faster.  Once granted, accelerated drug approvals are subject to withdrawal if a postmarketing study fails to confirm clinical benefit. The authors examined 18 cancer drugs that received accelerated FDA approval, but were found in postmarketing confirmatory trials to have no overall survival (OS) benefit. The FDA should withdraw approval for cancer drugs that are proven to have no clinical benefit.  (The JAMA Network)